Hympavzi

Marstacimab, the active ingredient in Hympavzi, is a monoclonal antibody presented as a subcutaneous formulation for subcutaneous use. It is indicated for the treatment of hemophilia A and hemophilia B, helping to improve clot formation and reduce bleeding episodes in affected patients.

GNH USA supplies Hympavzi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide, with a focus on quality assurance and regulatory compliance and reliable cold‑chain logistics for biologic products.

Hympavzi (Marstacimab) acts on the tissue factor pathway inhibitor (TFPI) to restore hemostasis in hemophilia patients.

Hemophilia A: improves clotting and reduces bleeding frequency in patients with factor VIII deficiency. Hemophilia B: enhances thrombin generation and lowers bleed rates in patients with factor IX deficiency. Hemophilia prophylaxis: provides ongoing protection against spontaneous bleeds when used as a preventive regimen.

Marstacimab may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Injection site erythema - Injection site pain - Headache - Nausea - Fatigue - Arthralgia

Serious or Rare Side Effects: - Thrombotic events (arterial or venous) - Severe hypersensitivity reactions (anaphylaxis) - Disseminated intravascular coagulation - Development of neutralizing antibodies - Paradoxical severe bleeding - Immune‑complex mediated vasculitis

When prescribing Hympavzi, clinicians should consider several safety and handling precautions.

Bleeding risk assessment: evaluate baseline bleeding frequency and factor levels before initiation. Thrombosis monitoring: watch for signs of arterial or venous thrombosis during therapy. Allergy screening: confirm no prior hypersensitivity to monoclonal antibodies. Concomitant anticoagulants: avoid or adjust doses of anticoagulant or antiplatelet agents. Pregnancy and lactation: use only if potential benefit justifies potential risk, as safety data are limited. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Marstacimab can interact with other medicines that affect coagulation or immune response.

Major Interactions (Avoid): - Concurrent use of direct oral anticoagulants (e.g., rivaroxaban, apixaban): may increase bleeding risk. - Combined therapy with activated pro‑coagulant agents (e.g., recombinant factor VIIa): may precipitate thrombosis. - Strong immunosuppressants (e.g., rituximab): may reduce efficacy of Marstacimab.

Moderate Interactions (Monitor Closely): - Antiplatelet drugs (e.g., aspirin, clopidogrel): monitor for altered bleeding patterns. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may increase mucosal bleeding. - Vaccines (live attenuated): assess timing to avoid immune interference.